Skip to main content

Taysha Gene Therapies, Inc.

TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001806310

No open-market purchases or sales by Taysha Gene Therapies, Inc. insiders were filed in the last 90 days; 204 institutions reported holding it in 13F filings for Q3 2026, worth $1.54B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$1.21B
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +2 vs. previous quarter
204
13F valueReported value at the end of Q3 2026
$1.54B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$9.77M
+17.3% year over year
Net income, FY2025
-$109.0M
No comparable prior period
Free cash flow, FY2025
-$93.8M
No comparable prior period
Revenue, Q3 FY2026
$0
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $109.0M (1115.3% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
53.5M
Shares sold short
Change
+2.23M
+4.4% vs. previous
Days to cover
14.76
At average daily volume

Superinvestors holding TSHA, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding TSHA at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Taysha Gene Therapies, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 10, 2026 (view filing)6:54 PM ETJul 10Same dayNagendran SukumarPresident and Head of R&DSSale−200.0K$6.24−$1.25M−17.6%936.4K after10b5-1
Apr 13, 2026 (view filing)Apr 103 daysNagendran SukumarPresident and Head of R&DSSale−200.0K$4.46−$892.0K−15.0%1.14M after10b5-1
Feb 6, 2026 (view filing)Feb 42 daysAlam KamranCHIEF FINANCIAL OFFICERSSale−1.66K$4.52−$7.48K−0.1%1.44M after
Jan 27, 2026 (view filing)Jan 23-264 daysAlam KamranCHIEF FINANCIAL OFFICERSSale−102.8K$4.72−$485.0K−6.6%1.44M after2 lots
Jan 27, 2026 (view filing)Jan 23-264 daysNagendran SukumarPresident and Head of R&DSSale−116.0K$4.72−$547.5K−8.1%1.32M after2 lots
Jan 27, 2026 (view filing)Jan 23-264 daysNolan Sean P.Chief Executive OfficerSSale−178.1K$4.72−$840.2K−5.8%2.91M after2 lots
Jan 14, 2026 (view filing)Jan 122 daysNagendran SukumarPresident and Head of R&DSSale−200.0K$4.71−$942.0K−16.6%1.01M after10b5-1
Dec 1, 2025 (view filing)Nov 28-Dec 13 daysNagendran SukumarPresident and Head of R&DSSale−370.2K$4.58−$1.70M−26.9%1.01M after2 lots
Sep 12, 2025 (view filing)Sep 102 daysNagendran SukumarPresident and Head of R&DSSale−200.0K$3.23−$646.0K−16.6%1.01M after10b5-1
Aug 22, 2025 (view filing)Aug 211 dayNagendran SukumarPresident and Head of R&DSSale−57.1K$2.85−$162.6K−4.7%1.17M after

Top 10 13F holders, Q3 2026

See all 204 holders

The largest institutional positions in Taysha Gene Therapies, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding TSHA in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Ra Capital Management, L.P.30,435,190$148.2M1.49%+6,879,542+29.2%Added
Goldman Sachs Group Inc25,115,519$122.3M0.01%+2,402,401+10.6%Added
Avoro Capital Advisors LLC23,888,888$116.3M1.20%00.0%Unchanged
BlackRock, Inc.22,651,999$110.3M0.00%+1,960,072+9.5%Added
Vestal Point Capital, LP18,045,000$87.9M2.27%−1,370,000−7.1%Reduced
Morgan Stanley15,722,735$76.6M0.00%−764,744−4.6%Reduced
RTW Investments, LP13,560,258$66.0M0.67%00.0%Unchanged
FMR LLC13,558,965$66.0M0.00%+222,552+1.7%Added
Vanguard Capital Management LLC12,540,069$61.1M0.00%+61,474+0.5%Added
State Street Corp11,380,707$55.4M0.00%−41,213−0.4%Reduced

Holders of 5% or more of TSHA

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Taysha Gene Therapies, Inc..

Largest holders of TSHA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Ra Capital Management, L.P.13G/A9.90%32.8M shares0.00 ppfrom 9.90%Aug 25, 20237 filingsNov 16, 2026SEC
Manning Paul B13D/A9.80%25.6M shares–Nov 2, 20223 filingsJun 3, 2025SEC
RTW Investments, LP13G/A7.00%20.7M shares−1.30 ppfrom 8.30%Feb 14, 20246 filingsMay 15, 2026SEC
BlackRock, Inc.13G/A6.50%17.9M shares+1.30 ppfrom 5.20%Oct 22, 20244 filingsJan 21, 2026SEC
Vestal Point Capital, LP13G/A6.30%18.0M shares+1.30 ppfrom 5.00%Feb 17, 20262 filingsMay 15, 2026SEC